From Invasive to Non-Invasive: Revolutionizing Stroke Treatment with Ultrasound
This video outlines the journey of Dr. Ameer Hassan and co-founder as they explored and developed ultrasound-based treatments for stroke.
Initially, they experimented with invasive ultrasound catheters aimed at breaking up clots within blood vessels to improve recanalization more effectively than existing methods like IV thrombolytics or mechanical thrombectomy.
Early trials in 2013 were negative for mechanical thrombectomy, leading to doubts about invasive catheter-based stroke treatments. However, positive trial results in 2015 renewed interest in these methods, highlighting issues in earlier studies such as unconfirmed vessel occlusion and the use of stiff, difficult-to-navigate ultrasound catheters.
The team pivoted then from invasive catheters to non-invasive external ultrasound probes, realizing that ultrasound technology could be utilized externally to break up clots without the need for catheter insertion. This shift marked a critical innovation in stroke treatment technology, emphasizing safety, reusability, and cost-effectiveness.
Highlights
- 🔬 Discovery of ultrasound as a promising stroke treatment method surpassing IV thrombolytics and mechanical thrombectomy.
- ⚠️ Initial 2013 trials of mechanical thrombectomy showed negative results, causing skepticism about invasive interventions.
- 💡 Insight that many earlier trials failed to confirm vessel occlusion and used suboptimal, stiff ultrasound catheters.
- 🤝 Mentorship and collaboration played a key role in reevaluating the ultrasound catheter device’s limitations.
- 🔄 Technological pivot from invasive catheters to non-invasive external ultrasound probes.
- 💰 Emphasis on device reusability to reduce patient costs and hospital expenses.
- 🚀 Eureka moment driven by co-founder’s simple question led to innovation in non-invasive stroke treatment.
Automated Non-Invasive Ultrasound Therapy for Rapid Stroke Treatment
This video discusses a groundbreaking non-invasive stroke treatment technology that utilizes transcranial Doppler ultrasound combined with automated ultrasound-based therapy called hypocrisy to locate and break up blood clots in the brain.
The patient lies flat and intubated while two probes—one on the same side as the clot (ipsilateral) and one on the opposite side (contralateral)—are placed to identify and treat the clot. This automated system simplifies the procedure to a single-button activation that shatters clots into tiny fragments (250 microns or smaller), significantly improving upon existing treatments like intravenous tissue plasminogen activator (IV tPA), Tenecteplase, or mechanical thrombectomy.
The goal is to achieve successful recanalization in about 70% of treated patients, with fewer hemorrhagic complications. Because the treatment is non-invasive and easy to administer, it can be expanded from specialized comprehensive stroke centers to the much larger network of primary stroke centers.
This expansion could dramatically increase access to effective stroke care, reduce treatment times, improve patient outcomes, and decrease hospital stays, ultimately saving more brain function by addressing strokes earlier and more efficiently.
Highlights
- 🧠 Innovative non-invasive ultrasound technology treats brain clots automatically and effectively.
- 🎯 Two probes (ipsilateral and contralateral) use transcranial Doppler to locate and target clots precisely.
- 💥 Histotripsy breaks clots into tiny fragments (250 microns or less), enhancing treatment efficacy.
- ⏱ Single-button activation allows rapid treatment, reducing critical time delays in stroke care.
- 🏥 Potential to expand from 250 comprehensive stroke centers to 2,500 primary stroke centers nationwide.
- ⚠️ Lower hemorrhage rates compared to traditional clot-busting therapies and mechanical thrombectomy.
- 💡 Faster treatment correlates with better functional recovery and shorter hospital stays.
Overcoming Delays in Stroke Care with Transcranial Doppler Automation
This Video discusses the challenges and limitations of current stroke treatments, particularly focusing on intravenous (IV) thrombolytics and mechanical thrombectomy. IV thrombolytics, which dissolve clots when administered early, are only used in about 3-7%, or up to 10% of stroke cases according to some literature, and have a limited success rate—working approximately 30% of the time overall and as low as 6% in cases involving the carotid terminus.
Mechanical thrombectomy, a procedure that physically removes clots, has a higher success rate of about 90%, but its effectiveness is often diminished by significant delays in treatment. These delays occur because many patients first arrive at primary stroke centers that cannot perform thrombectomy and require transfer to specialized centers, which adds hours to treatment time. Every two-minute delay results in the loss of approximately 2 million neurons, highlighting the critical importance of rapid intervention.
Dr. Ameer Hassan also explains a new approach involving transcranial Doppler (TCD) ultrasound as an automated method to detect clots. They emphasize that TCD can identify clots in 70-80% of patients, although anatomical variations such as skull thickness and vessel tortuosity can make detection difficult in about 10% of cases. If the clot cannot be detected by TCD, treatment is aborted to avoid futile intervention. This suggests a more targeted and efficient stroke management strategy that relies on early and accurate clot detection to improve outcomes.
Highlights
- 🧠 IV thrombolytics treat only 3-10% of stroke cases and have limited effectiveness, especially in carotid terminus strokes.
- 🚑 Mechanical thrombectomy works in 90% of cases but faces delays due to patient transfer between centers.
- ⏱️ Every 2-minute delay in treatment causes the death of 2 million neurons, emphasizing urgency.
- 🦴 Skull thickness and vessel tortuosity affect the ability to detect clots using transcranial Doppler ultrasound.
- 📊 Transcranial Doppler can detect clots in 70-80% of stroke patients, enabling more targeted treatment.
- ❌ If TCD fails to locate a clot, treatment is aborted to avoid unnecessary procedures.
- ⚙️ Automation with TCD offers a promising new approach to improve stroke treatment efficiency and outcomes.
$4M Investment Fuels Breakthrough Ultrasound Tech for Stroke and Vascular Treatment
This video outlines the progress and future potential of a medical technology designed to treat vascular occlusions and other related medical conditions. The team has successfully raised four million dollars from friends, family, and medical specialists including neurointerventionalists, neurosurgeons, and neurologists nationwide.
They have completed significant preclinical work, reaching version 3.0 of their device, which now integrates a transcranial Doppler interface. This advancement has been tested successfully in animal models, specifically pigs, where they treated artificially created clots in carotid vessels, achieving complete recanalization. The next critical step is to secure institutional funding to prepare for human clinical trials.
Beyond treating large vessel occlusions, this technology shows promise for broader applications across various diseases. One such application is modifying the blood-brain barrier to facilitate intra-arterial chemotherapy for brain tumors. Another important use could be liquefying clots in intracerebral hemorrhages and intraventricular hemorrhages, conditions with high mortality rates due to the inability of the body to naturally clear the blood.
The device could help liquefy these clots, enabling the cerebrospinal fluid to recirculate and clear the hemorrhage more effectively. Additionally, this technology could be adapted for treating pulmonary embolisms and deep vein thromboses (DVTs), which may be easier procedures since they do not involve navigating through bone but rather through muscle tissue.
Overall, this technology represents a versatile platform with potential applications across multiple critical vascular and neurological conditions.
Highlights
- 💰 Raised $4 million from friends, family, and medical experts for development.
- 🐖 Completed successful animal trials in pigs, achieving full clot recanalization.
- 🧠 Developed version 3.0 with integrated transcranial Doppler interface.
- 🧬 Potential to modify the blood-brain barrier for targeted chemotherapy delivery.
- 💉 Could liquefy clots in intracerebral and intraventricular hemorrhages to improve outcomes.
- 🚑 Possible application in treating pulmonary embolism and deep vein thrombosis.
- 🔜 Preparing for first-in-human clinical trials pending institutional funding.
Global Access Gap in Stroke Care and the Push for Democratized Treatment
This video focuses on the critical issue of stroke treatment accessibility worldwide and the potential impact of new technologies in improving outcomes.
Dr. Ameer Hassan, an expert and immediate past president of the Society of Vascular and Interventional Neurology (SVIN), highlights the current disparity in access to mechanical thrombectomy—a key stroke therapy—between the United States and the rest of the world.
While about 30% of Americans have timely access to this treatment, globally only around 2.7% do, leaving millions underserved.
Dr. Ameer Hassan emphasizes the importance of democratizing stroke care by making advanced treatment technologies widely available, including in low-income countries and even directly in ambulances via mobile stroke units.
This vision aims to drastically improve stroke outcomes by enabling rapid diagnosis and treatment, particularly for patients suffering from large vessel occlusions, thereby reducing disability and mortality associated with strokes.
Highlights
- 🧠 Stroke is a major global health challenge with significant treatment access disparities.
- 🌍 Only 2.7% of people worldwide have timely access to mechanical thrombectomy for stroke.
- 🇺🇸 In the U.S., approximately 30% of stroke patients can access mechanical thrombectomy within the crucial time window.
- 📉 70% of Americans and over 97% globally lack timely access to this life-saving treatment.
- 🏥 The goal is to expand stroke therapy availability in comprehensive and primary stroke centers worldwide.
- 🚑 Innovative mobile stroke units equipped with diagnostic and treatment tools could revolutionize pre-hospital stroke care.
- 💡 Democratizing stroke care technology could significantly reduce stroke-related disability and death.